A transgenic inducible GFP extracellular-vesicle reporter (TIGER) mouse illuminates neonatal cortical astrocytes as a source of immunomodulatory extracellular vesicles

Victoria N. Neckles1, Mary C. Morton1, Jennie C. Holmberg1, Aidan M. Sokolov1, Timothy Nottoli2, Don Liu3 & David M. Feliciano1

Extracellular vesicles (EVs) are cellular derived particles found throughout the body in nearly all tissues and bodily fluids. EVs contain biological molecules including small RNAs and protein. EVs are proposed to be transferred between cells, notably, cells of the immune system. Tools that allow for in vivo EV labeling while retaining the ability to resolve cellular sources and timing of release are required for a full understanding of EV functions. Fluorescent EV fusion proteins are useful for the study of EV biogenesis, release, and identification of EV cellular recipients. Among the most plentiful and frequently identified EV proteins is CD9, a tetraspanin protein. A transgenic mouse containing a CRE-recombinase inducible CAG promoter driven CD9 protein fused to Turbo-GFP derived from the copepod Pontellina plumata was generated as an EV reporter. The transgenic inducible GFP EV reporter (TIGER) mouse was electroporated with CAG-CRe plasmids or crossed with tamoxifen inducible CAG-CRe-eR1/2 or nestin-CRe-eR1/2 mice. CD9-GFP labeled cells included glutamine synthetase and glial fibrillary acidic protein positive astrocytes. Cortical astrocytes released ~136 nm EVs that contained CD9. Intraventricular injected EVs were taken up by CD11b/IBA1 positive microglia surrounding the lateral ventricles. Neonatal electroporation and shRNA mediated knockdown of Rab27a in dorsal subventricular zone NSCs and astrocytes increased the number of CD11b/IBA1 positive rounded microglia. Neonatal astrocyte EVs had a unique small RNA signature comprised of morphogenic miRNAs that induce microglia cytokine release. The results from this study demonstrate that inducible CD9-GFP mice will provide the EV community with a tool that allows for EV labeling in a cell-type specific manner while simultaneously allowing in vivo experimentation and provides evidence that EVs are required immunomodulators of the developing nervous system.

Extracellular vesicles (EVs) are nanometer sized particles that are released from numerous central nervous system cell types and are implicated in a wide range of neurological diseases1. Work focused on brain development has identified EVs within fetal, perinatal, and adult cerebrospinal fluid (CSP)2-3. One source of EVs are neonatal subventricular zone (SVZ) neural stem cells (NSCs)4. NSC EVs act as an immunomodulator that are taken up by CD11b/IBA1 positive immune cells in the SVZ during perinatal development4-5. NSC EVs facilitate transcriptional network re-wiring of microglia and subsequent release of cytokines.
SVZ NSCs begin to diminish and recede in number as rodents age. In humans, SVZ NSCs exhaust by 18 months of age. Although the embryonic brain is colonized by microglia early in embryonic development, a band of microglia appears within the ventricular zone near the end of neurogenesis, and a population of CD11b positive microglia localizes to the postnatal rodent SVZ. As neurogenesis slows and dorsal SVZ NSCs generate astrocytes, many SVZ microglia disperse. This coincides with the dispersion, activation state conversion, and morphological maturation of microglia. The mechanisms responsible for microglia dispersion and maturation are unclear.

A mechanism that could partially account for changes in microglia is that sources of EVs also change. As the number of SVZ NSCs decreases, fewer NSC EVs are produced. Around the same time, lower cortical layer astrocytes are produced from dorsal SVZ progenitors and upper cortical layer astrocytes are produced by additional progenitors. Perinatal astrocytes could in theory be an additional EV source. In fact, SVZ NSCs are a special type of astrocyte, they are SVZ astrocytes. SVZ NSCs and cortical astrocytes also share cellular ontology and overlap in biochemical markers. Moreover, astrocytes can generate neurons upon transplantation to a permissive environment, for example, the SVZ. Upon introduction of specific transcription factors, for example SOX2, astrocytes become neurogenic. Predictably, during the neonatal period, astrocytes, particularly reactive astrocytes, are released from their gliogenic fate potential.

In vivo microglia localizes to the postnatal rodent SVZ. As neurogenesis slows and dorsal SVZ NSCs generate astrocytes, are released from their gliogenic fate potential.

In vivo EV studies are commonly performed in vitro because there are few tools to study EVs in vivo and therefore evidence of elaborate hypotheses requires further substantiation. In vitro electroporation of DNA plasmids that encode for fluorescent EV labels has at least in part addressed this issue. However, there remains considerable evidence of elaborate hypotheses requires further substantiation.

In vivo and whole tissue imaging with two-photon microscopy (Fig. 1C). The expression and distribution of CD9-GFP within cells was examined in cultured fibroblasts. CD9-GFP expression was induced only when cells were cultured with tamoxifen (Fig. 1D). Tissues were sectioned, subjected to immunochemistry, and imaged by confocal microscopy study and CD9-GFP expression was confirmed within each tissue. The results from these experiments demonstrate tissue and cell-type dependent recombination and CD9-GFP expression.

TIGER mice were crossed with Nestin-Cre-ERT2 and Tomato+/- mice and tamoxifen given three times at P8 and sacrificed at P11 which corresponds to periods of peak astrogliogenesis (Supplemental Fig. 3A–G). CD9-GFP was detected in cells with an astrocyte-like morphology in the cerebral cortex following tamoxifen injection (Supplemental Fig. 3C–G). The results from these experiments demonstrate that CD9-GFP expression is specific when using a highly selective promoter driven CRE system and confirm that recombination occurs in cells co-expressing tomato.
Brains from tamoxifen injected CAG-CRE-ER\textsuperscript{T2} × TIGER mouse were subjected to CLARITY and two-photon microscopy. CD9-GFP labeled cells in the cortex were reminiscent of the cortical astrocyte-like cells seen in TIGER × Nestin-CRE-ERT\textsuperscript{2} × Tomato\textsuperscript{+/+} mice (Fig. 2A). To determine the identity of these cells, brains were subjected to immunohistochemistry for the astrocyte marker protein GFAP which is expressed in a small population of astrocytes around the corpus callosum and SVZ under resting conditions. CD9-GFP and GFAP co-localization was found in lower cortical layers near the corpus callosum (Fig. 2B–F). All CD9-GFP positive cortical cells were also positive for the astrocyte marker, Glutamine Synthetase (GS) (Fig. 2G,H). High magnification highlighted the astrocyte-like morphology of these cells (Fig. 2I).

The ability of astrocytes to express CD9 was confirmed by culturing TIGER × Nestin-CRE-ERT\textsuperscript{2} × Tomato\textsuperscript{+/+} mice astrocytes electroporated with CRE, by culturing astrocytes from TIGER × Nestin-CRE-ERT\textsuperscript{2} mice injected with tamoxifen, and by CD9-GFP and tomato electroporation of astrocytes (Fig. 2J–L). These results demonstrate that astrocytes can express CD9.

It was unclear whether CD9-GFP expression in astrocytes was indicative of their potential to release EVs or was based on the absorption, distribution, metabolism, and excretion of tamoxifen as well as cell type specific expression of CAG-CRE-ER\textsuperscript{T2}. Cortical CD9 expression was determined using two antibodies to CD9 and reliably detected bands between 20–25 kDa and ~37 kDa that increased in prevalence from e15 to adulthood (Fig. 3A, data not shown). To confirm that astrocytes express CD9 we performed bioinformatic analysis using two databases and validated CD9 mRNA expression in astrocytes by single cell and by ribotag RNA-sequencing (Fig. 3B,C).\textsuperscript{20,21} EVs from neonatal cortical astrocytes were collected from cultures and subjected to western blot. Astrocytes produced EVs that were CD9 and CD63 positive (Fig. 3D). Astrocytes were next cultured from neonatal mice and media collected, pre-cleared, and subjected to nanoparticle tracking analysis. Media contained a singular prominent unimodal EV peak at ~136 nM (Fig. 3E). These results demonstrate that astrocytes produce CD9 positive EVs.

Previous work has demonstrated that intraventricular injected NSC EVs are taken up by microglia. Therefore, intraventricular injection of Dil-labeled astrocyte EVs was performed. Similar to NSC EVs, astrocyte EVs were also taken up by CD11b/IBA1 positive immune cells having an elliptical morphology (Fig. 4A–D). Quantification revealed that 57.7% ± 7.30% of Dil labeled EVs colocalized with IBA1 positive microglia within the SVZ. A loss of function approach was developed using shRNA to Rab27a which is required for exosome biogenesis. Four Rab27a shRNAs were examined, one of which was confirmed to knockdown Rab27a in mouse Neuro-2a neuroblastoma cells \textit{in vitro} (Fig. 4M). tdTomato control or Rab27a shRNA encoding plasmids
were co-electroporated into P0 SVZ NSCs. In vivo Rab27a knockdown was assessed 48 hrs after electroporation by immunohistochemistry. Rab27a shRNA resulted in a 93% reduction in Rab27a expression that was statistically significant (Rab27a shRNA = 7.64% ± 1.45 vs. Control = 100% ± 29.34, P < 0.05, N = 4) (4N). Seven days post electroporation robust tdTomato expression was detected within dorsal SVZ NSCs having a basal radial projecting fiber that were nestin positive (Fig. 4E–H, data not shown). CD11b/IBA1 positive microglia were present within the SVZ and Rab27a knockdown resulted in similar numbers of CD11b/IBA1 positive microglia at P2. Electroporated dorsal NSCs give rise to astrocytes12. Between P2 and P7, the number of CD11b positive IBA1 positive microglia began to decrease (Fig. 4O). However, Rab27a increased the number of CD11b/IBA1 positive microglia in the SVZ (Fig. 4I–L,O). These results support a role for neonatal astrocyte EVs in regulating the number of CD11b positive microglia in the SVZ.

Previous work demonstrated that NSC EVs contain immunomodulatory small RNAs and regulate a transcriptional network that induces microglia to increase the synthesis and release of cytokines. As an unbiased approach to begin to examine astrocyte EV functions, small RNA sequencing of astrocyte EVs was also performed. It was not surprising that neonatal astrocyte EVs contained many of the same miRNAs identified in neonatal NSC EVs including Let-7 family members (Fig. 5A). To determine the similarity of astrocyte EVs to NSC EVs, small RNA signatures determined by small-RNA sequencing were subjected to hierarchical clustering. Astrocyte EVs clustered with astrocyte EVs whereas NSC EVs clustered together (Fig. 5B). A small group of miRNAs were significantly differentially represented in astrocyte EVs and NSC EVs, many of which were several-fold differentially expressed (Fig. 5C,D). It was tempting to speculate that based on the conservation of immunomodulatory miRNAs in astrocyte EVs and the temporal induction of CD9, that astrocyte EVs may have immunomodulatory and morphogenic properties similar to neonatal SVZ NSCs. To test this hypothesis, EVs from neonatal astrocytes were used to treat cultured microglia. Astrocyte EVs stimulated a unique microglia cytokine profile (Fig. 5E). Taken together, these results demonstrate that neonatal astrocytes generate CD9 positive EVs that are targeted to and modify microglia.

Figure 2. (A) Depth coded volumetric rendering of cerebral cortex of a TIGER × Nestin-CRE-ER12 mouse. Scale bar, 50 μm. (B–D) CD9-GFP (green) × CAG-CRE-ER12 brain sectioned and stained for GFAP (red) and counter-stained with TOPRO (blue) to label nuclei merged (B), CD9-GFP alone (C), and CD9-GFP/GFAP (D). Arrows point to cells with co-localization. Scale bar, 100 μm. (E,F) 20X image of CD9-GFP (green) CAG-CRE-ER12 brain sections stained for GFAP (red) and counter-stained with (E) or without (F) TOPRO (blue). Arrows point to colocalization. Scale bar, 50 μm. (G,H) Image showing CD9-GFP (green) from TIGER × CAG CRE ER12 brain sections stained for GS (red) and TOPRO (blue) (G) or CD9-GFP only (H). Arrows points to colocalization. Scale bar, 50 μm. (I) 63X image of cortex demonstrating CD9-GFP in astrocytes. Scale bar, 25 μm. (J) Astrocyte culture from TIGER × Tomato mice electroporated with CRE and counter-stained with TOPRO (blue). Scale bar, 50 μm. (K) Cultured astrocytes from TIGER mice and counter-stained with TOPRO (blue). Scale bar, 12.5 μm. (L) CD9-GFP (green) and tomato (red) electroporated astrocyte cultures to demonstrate morphology. Scale bar, 25 μm.
Discussion

Here we report the generation of an inducible CD9-GFP mouse. Tetraspanin proteins are useful for the isolation, characterization, and functional evaluation of EVs. A notable triad of exosome tetraspanin proteins includes CD9, CD63, and CD81.22–25 Overlap between these markers exists, although each can also demarcate unique vesicle populations25. CD9 and CD63 are found throughout the secretory pathway including in lysosomes and the cell membrane but are enriched within MVBs26. CD63 fluorescent fusion proteins have been used for over a decade to study EVs. Notable examples are the use of CD63-GFP to demonstrate that classical morphogens such as Hedgehog and Wingless are transferred with EVs27,28. CD63-GFP has been used to study exosomes in mammalian EVs, including from mouse, rat, and human cells. For example, CD63-GFP was used to demonstrate transfer of EVs from T cells through an immunological synapse to antigen presenting cells29. More recently, tag-GFP from copepods was fused to CD63 and used to create transgenic rats30. The expression of CD63-GFP is sustained from a ubiquitously activated CAG promoter (CAG-CD63-GFP)30. CAG-CD63-GFP was found in many tissues including within the heart, lung, and cortex, hippocampus and cerebellum of the brain. Moreover, CD63-GFP containing EVs could be isolated from biological fluids or from media conditioned from CD63-GFP expressing primary cell cultures30. A similar SOX2-CD63-GFP rat was generated although this model had a much more restricted developmental CD63-GFP distribution and was enriched in NSCs31. The TIGER mouse offers the primary advantage of combining ubiquitous expression with a CRE-inducible system and allows for cellular and temporal control of EV labeling. Expression therefore could be titrated to more cell types as demonstrated with CAG-CRE-ER22 or fewer as occurred with Nestin-CRE-ER22. Using CLARITY, robust in vivo labeling was demonstrated within a wide range of tissue types including spleen, heart, kidney, and brain. To our surprise, the subcellular distribution of CD9-GFP was frequently cell-type dependent. These results suggest that CD9 may label distinct EV subtypes, but this depends on the cell of origin.

A convergent cell-type labeled by CAG-CRE-ER22 and nestin-CRE-ER22 were astrocytes. Labeling within the brains of CAG-CRE-ER22 mice was robust by P10 as evidenced by CLARITY whole brain imaging. Cells had a

Figure 3. (A) Quantification of CD9 protein relative to AKT in cortical lysates at the indicated ages according to western blots of dorsal cortical lysates for CD9 and AKT as a loading control. The ~37 kDa (black bar) and 20–25 kDa (grey bar) CD9 bands were quantified. N = 3 independent biological replicates. (B) RNA sequencing reads for CD9 based on cell type listed. Astro. = Astrocyte, Endoth. = Endothelial cell, Micro. = microglia, Oligo Stem = Oligodendrocyte stem cell, Oligo New = immature oligodendrocyte, Oligo Myelin = Mature myelinating oligodendrocyte. (C) Quantification of astrocyte CD9 mRNA associated with active ribosomes from different regions and ages. Visual = visual cortex, Motor = Motor cortex, Somat. = Somatosensory cortex, Hypoth. = Hypothalamus, Cereb. = Cerebellum. (D) Western blots of astrocyte lysate and EVs for CD9 and CD63. (E) Nanosight particle tracking analysis frequency histogram of astrocyte conditioned media. Data are represented as mean ± SEM.
bushy appearance similar to astrocytes and when subjected to immunohistochemistry, labeled cells within the cortex were frequently positive for astrocyte markers GFAP or GS. These results led to the hypothesis that astrocytes from early cortical development release EVs. Astrocytes from the adult brain release EVs, however whether astrocytes release EVs during development was unknown. Here, cultured cortical astrocytes released EVs that were 136 nm in size and contained CD9 and CD63. CD9 expression was up-regulated within the cortex of the juvenile brain and into adulthood as quantified by western blot. Bioinformatic analysis confirmed astrocyte CD9 and CD63 expression which was confirmed by western blotting neonatal cortical astrocytes and cortical astrocyte EVs.

Microglia infiltrate the cortex after the first postnatal week. Neonatal NSC EVs can regulate microglia. Since dorsal SVZ NSCs give rise to astrocytes, it was hypothesized that astrocyte EVs might also regulate microglia.

Figure 4. (A–D) Images of coronal brain sections showing Dil (red) labeled EVs taken up by IBA1 (blue) and CD11b (green) positive microglia. (E,F) Tomato and control plasmid (blue) dorsal SVZ electroporations stained for CD11b (green) and IBA1 (magenta) at P7, 10x (E), 20x (F). (G,H) 20x magnification of E showing CD11b (green) and IBA1 (red) (G) or CD11b (H). (I,J) Tomato and Rab27a shRNA plasmid (blue) dorsal SVZ electroporations stained for CD11b (green) and IBA1 (magenta) at P7, 10x (I), 20x (J). (K,L) 20x magnification of I showing CD11b (green) and IBA1 (red) (K) or CD11b (L). (M) Western blot of Rab27a following shRNA mediated knockdown. (N) Images of coronal section stained for Rab27a (green) following control or Rab27a shRNA and tomato (magenta) co-electroporation at P0 and sacrificed 48 hrs later. (O) Quantification of CD11b positive microglia at P2 and P7 following control or Rab27a shRNA electroporation. Data are represented as mean ± SEM. ****p < 0.0001 A, E, I scale bar, 100 μm. B–D, F–H, J–L, N scale bar, 50 μm.
ability of astrocyte EVs to mobilize peripheral immune cells also supports this hypothesis. In further support of this hypothesis, the majority of injected DiI labeled astrocyte EVs were taken up by CD11b positive IBA1 positive microglia. The possibility that other cell types may take up astrocyte EVs cannot be ruled out. In addition, by seven days post-electroporation, Rab27a knockdown increased the number of CD11b/IBA1 microglia. These results are surprising given the activated phenotype of microglia cultures exposed to NSC EVs. As opposed to

Figure 5. (A) Top most abundant miRNA reads from astrocyte EVs. (B) Hierarchical clustering analysis of small RNAs from neonatal NSC and astrocyte EVs. (C) Statistically significant up and down-regulated miRNAs. (D) Differential expression profile of individual miRNAs. (E) Cytokine profiles from microglia condition media. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.0001.
inducing an activated CD11b state, these results suggest those microglia having an activated state selectively take up EVs and that this uptake is associated with conversion to a non-CD11b state or dispersion from the SVZ.

To the surprise of the investigators, EVs from NSCs and astrocytes had considerable overlap, including members of the Let-7 family, yet clearly had a distinct signature. In relation to this signature, the effect of astrocyte EVs induced microglia cytokine profiles that differed from NSC EV induced responses. It is unclear at this time what accounts for the differential immune responses to EVs but could be related to the RNA signature present within the cell types. It would appear that molecules that function similar to PD-L1 or noncoding RNAs such as hY4 may be responsible for differences in immune responses33,34. Identifying differences in EV content and immune responses will prove critical in developing novel immunomodulatory strategies for regulating the neuro-immune axis.

Methods

Animals. The experimental protocols were approved by the Clemson University Institutional Animal Care and Use Committee. Experiments were performed according to guidelines set forth by the Clemson University Institutional Animal Care and Use Committee and NIH Guide for the Care and Use of Laboratory Animals. For primary cell culture experiments and for neonatal electroporations, pregnant CD-1 mice were obtained from Charles River Laboratories. The following strains were acquired from Jackson Laboratories and crossed to CD9 mice: Tomato, B6.Cg-Gt(Rosa)26Sortm9(CAG-tdTomato), Hze/J Stock No: 007909 A19; Nestin-CRE-ER22, C57BL/6-Tg(Nes-cre/ERT2)KEsc/J, Stock No: 016261; CAG-CRE-ER22, B6.129-Gt(Rosa)26Sortm1(cre/ERT2) Tjy/J, Stock No: 008463. Mice were housed under pathogen-free conditions with a 12-hr light/dark cycle. Pooled samples of both genders were used.

Astrocyte culture. 24 hrs prior to culture initiation, wells of a sterile 6 well plate were coated with 2 μg/mL of Poly-L-Lysine stock solution (ScienCell; Catalog #0413) in dPBS according to the manufacturer’s instructions. Wells were then washed twice in nuclease free, sterile water prior to plating cells. P4 CD1 mouse pups were euthanized and dorsal cortices were removed. Using a scalpel, cortices were chopped into pieces, and placed into a 15 ml conical tube containing 2 mL of cold DMEM on ice. 400 μL of Trypsin/EDTA was added to the 2 mL of DMEM and placed in the incubator for 10 mins. Cells were triturated with three Pasteur pipettes fire polished to have decreasing bore sizes. 400 μL of trypsin inhibitor was added. Samples were then centrifuged at 200 × g for five mins. The supernatant was disposed of and the pellet was resuspended in 2 mL of warm DMEM for an additional centrifugation step of 200 × g. After decanting the warm DMEM, 10 mL of astrocyte media was added, and the pellet was resuspended. 10 mL of astrocytes in solution was added to a T75 flask containing fresh 15 mL of DMEM and placed in the incubator for 10 mins. Cells were triturated with three Pasteur pipettes. The media was exchanged for fresh astrocyte media (2% Fetal Bovine Serum, 100 U/mL Pen-strep, Astrocyte Culture Media [ScienCell; Catalog #1801]). Cultures were place in a 37 °C incubator with 5% CO2. After 24 hrs, half of the culture media was replaced with fresh astrocyte culture media. 48 hrs after culture initiation, culture media was collected and used for luminescent assays and extracellular vesicle isolation.

Small RNA sequencing. RNA was isolated by Trizol extraction and SeraMir Exosome RNA column purification (Systems Biosciences). Samples were quantified using the Agilent Bioanalyzer small RNA assay. Libraries were prepared according to manufacturer’s protocol (Illumina small RNA preparation kit). Samples were subjected to 1 × 75 bp single-end reads at an approximate depth of 10–15 million reads per sample on an Illumina Hi-Seq. Aligned reads are analyzed with Banana Slug Analytics Platform (University of California at Santa Cruz).

CLARITY. Tissues were fixed in 4% paraformaldehyde overnight at 4 °C, and subsequently washed for 15 mins in PBS three times at room temperature. Samples were incubated overnight in a hydrogel monomer solution made up with the X-Clarity Hydrogel Solution kit (Logosbio; Catalog #C1310X). The following day, tissue embedded in the hydrogel monomer was placed within the X-Clarity Logos Polymerization System (Logosbio; Catalog #C20001) for three hrs. Tissues were then briefly washed in PBS at room temperature and placed into the X-Clarity Tissue Clearing System (Logosbio; Catalog #) filled with Electrophoretic Tissue Clearing Solution (Logosbio; Catalog #C13001). Tissue cleared within 8 hrs. The tissue was then washed in room temperature PBS overnight, incubated in X-Clarity Mounting solution (Logosbio; Catalog #C13101) at 37 °C for 30 mins to an hr, and imaged using a Leica SP8 Multiphoton Confocal.

EV Isolation and labeling. Primary astrocyte cell culture media was subjected to differential centrifugation. Samples were pre-cleared to remove dead cells and debris by performing a 300 × g centrifugation for 10 mins and the supernatant was transferred to a new tube and centrifuged at 2,000 × g for 10 mins. Finally, the media was subjected to a 100,000 × g spin at 4 °C in a Beckman Coulter Optima MAX-XP with a TLA 100.3 rotor for 90 mins (P100 fraction). Centrifugation tubes were weighed and balanced with dPBS prior to centrifugation. Pellets were re-suspended in 25 μL 2% SDS in RIPA buffer containing protease and phosphatase inhibitor cocktail for western blot analysis or 50 μL dPBS for nanoparticle tracking analysis or microglia treatment. Astrocyte EVs were incubated with 0.2 μg prefiltered Dil (ThermoFisher Scientific, V22889) at 1:1000 dilution (1 μM) for 10 min at RT. Samples are placed into 2.0 mL of dPBS and recentrifuged at 100,000 × g at 4 °C for 30 min. Supernatant was removed and fresh sterile dPBS was added to EVs and vortexed. A Hamilton Syringe with Neuros adapter
was loaded with 1–2 μL of DiI-labeled EVs (5.52–11.4 × 10⁷ EVs). P0 CD1 mouse pups are anesthetized on ice for 5 min until pup is not ambulatory. Injections were performed by locating the sagittal suture of the developing skull along the midline of the brain. Hamilton Neurosyringe needle was placed near the rostral portion of the brain at the midline. The needle was inserted approximately 1 mm laterally and 0.5 mm caudally into the lateral ventricle approximately 2 mm deep. 1–2 μL of DiI-labeled EVs (5.52–11.4 × 10⁷ EVs) were injected into the lateral ventricles. Pups were immediately placed on heating pads for 5 min. Once ambulatory, pups were placed with mothers and sacrificed 1–7 days later.

**Immunohistochemistry.** Tissue was harvested and fixed in 4% PFA overnight at 4 °C. Tissue was washed for 1 hr at room temperature in PBS, mounted in 3% agarose, and sectioned into 200 μm thick sections with a Leica VTS 1000 vibratome. Sections were subsequently blocked for an hr in blocking solution (PBS, 0.1% Tween-20, 0.1% Triton-X 100, and 2% BSA). Sections were washed with 0.1% Tween-20 in PBS three times for a total of 15 mins. Sections were incubated in antibody solution (0.1% Tween-20 and 2% BSA in PBS) along with primary antibodies overnight at 4 °C. The following day, slices were washed for 30 min with three exchanges of wash buffer. Sections were incubated in antibody solution with secondary antibodies for 1 hr at room temperature or overnight at 4 °C. Following secondary antibody incubation, sections were washed for 10 min in wash buffer for a total of five times and once in PBS for 10 min prior to being mounted. Antibodies used were GFAP (Cell Signaling: Catalog #G2781), Rab27a (Cell Signaling: Catalog# D7Z9Q), Glutamine Synthetase (Sigma Aldrich: Catalog #G2781), Rab27a (Cell Signaling: Catalog# D7Z9Q).

**Quantification of microglial cells.** The number of CD11b+ microglia were quantified in FIJI (Image J) using the cell counter plugin. Confocal Z sections were loaded in FIJI, individual colored channels split, and converted into RGB images. CD11b+ microglia were quantified by hand and tracked by the cell counter plugin.

**Quantification of DiI uptake by microglia cells.** Images were loaded onto FIJI (Image J). Images were converted to a composite image. Z sections, selected based on DiI and IBA1 staining, were max Z projected. Confocal color channels were split. The DiI and IBA1 channels were thresholded, 0–255, to account for background. The colocalization threshold feature was used to produce a colored image showing colocalization. The image was then converted to an 8-bit image, inverted, and thresholded to visualize only co-localized particles. Particle analysis was then used to quantify the number of DiI and IBA1 colocalized particles. Analysis was also performed on the thresholded DiI image to quantify the total number of DiI particles. The percentage of co-localized DiI particles was in relation to the total number of DiI particles. Three Z sections per image were used to calculate the average percentage of colocalized particles. These values were then inserted into GraphPad Prism 7.04 to generate a graph.

**Quantification of Rab27a Knockdown.** 20x confocal images were loaded into FIJI software and max Z Projected. Individual channels were split and subjected to automated particle analysis using the particle analysis plugin. Particle size was set from 1 to infinity and the mean number of particle sizes and standard error mean were documented.

**Electroporations.** Electroporations were performed as described previously⁶. Briefly, P0 mice were injected with CAG-CRE, CAG-tdTomato, and/or Rab27a shRNA plasmid into the lateral ventricle of the subventricular zone. Pups were then electroporated with a BTX ECM 830 Square Wave Pulse generator and tweezertrodes (Harvard Apparatus). Electroporations were targeted to dorsal SVZ neural stem cells by placing the positive electrode on the lambda suture of the skull.

**Nanoparticle tracking analysis.** Samples were shipped to the Nanomedicine Characterization Core facility in the Center for Nanotechnology in Drug Delivery at the University of North Carolina (UNC) Chapel Hill. Samples were prepared in a laminar flow hood and thawed at RT. Sample dilutions were based on an initial run with PBS, 10 mM salt. Samples were loaded onto a pre-cleaned and pre-warmed Nanosight NS 500 nanoparticle characterization system (NanoSight, UK) equipped with a 532-nm laser and a 565-nm long pass filter. The Nanosight NS 500 was calibrated with 100 nm polystyrene latex microsphere standards (Nanosight, UK), and readings were acquired at 23.3 °C. Values were entered and graphed using GraphPad Prism 7.04 software.

**Long range PCR.** DNA was isolated using the Qiagen DNeasy Blood and Tissue Kit (250) (Catalog #69506). Briefly, samples were placed into a microcentrifuge tube with buffer ATL and Protein Kinase A. Samples were incubated at 56 °C and vortexed every hr until tissue became transparent. Once the tissue is transparent, buffer AL and ethanol were added to the samples. The mixture was then pipetted into a DNeasy mini spin column and centrifuged at 6,000 × g for one min. The column is then placed into a new collection tube with AW1 and centrifuged at 6,000 × g for one min. The collection tube is replaced again, buffer AW2 is added to the sample, and centrifuged at 20,000 × g for three mins. To ensure that the sample is dry, the flow through is removed and the sample is centrifuged again for three mins at 2,000 × g. The DNeasy mini spin column is then placed into a 1.5 mL microcentrifuge tube and 50 μL of buffer AE is pipetted directly onto the membrane. The samples are then incubated at room temperature for 5 mins and sequentially centrifuged at 6,000 × g for one min. This step is repeated using the flow-through. The samples were then quantified with a NanoDrop spectrophotometer to ensure that the DNA concentration was at least 10. Samples are stored at −20 °C. Using the Qiagen Long Range PCR Kit a master mix consisting of 5 μL Long Range PCR Buffer, 2.5 μL dNTP mix, 10 μL 5X Q Solution, 0.2 μL of each primer, 0.4 μL LongRange PCR Enzyme Mix, and enough RNase Free Water to make the mix 50 μL total per reaction. 49 μL of master mix was added to a PCR tube along with 1 μL of DNA. The samples were then placed into a thermocycler. Following amplification of the DNA, samples were loaded into a gel with 1X Blue Juice
and run at 100 V for 20–30 mins. The primers for 5′ targeting are 5′-CGCTTTAAAGAAGGCTGTG-3′ and 5′-TCATCAAGGAAACCTGGAC-3′ and for 3′ targeting are 5′-AACGACTGTCCTGCTCTCA-3′ and 5′-TAGTTGCCAGCCTCGTTTTGTT-3′.

Western blot. Samples were lysed in RIPA buffer containing 2% SDS, and protease and phosphatase inhibitor cocktail. Samples were placed on ice, sonicated, centrifuged and supernatants placed in a fresh tube. Protein samples diluted in Laemmli were run on 10% polyacrylamide gels and transferred to PVDF membranes using a Bio-Rad PROTEAN gel system. Membranes were blocked in TBS, 0.1% Tween-20, and 5% milk and incubated with the following antibodies: CD9 (Systems Biosciences, 1:1,000), CD63 (Systems Biosciences, 1:1,000), Rab27a (Cell Signaling, 1:1,000), pan-AKT (1:1,000, Cell Signaling). Horseradish peroxidase conjugated secondary antibodies were used at a concentration of 1:3,300. Membranes were incubated with Enhanced Chemiluminescent Substrate (Pierce) and signal detected with Amersham Hyperfilm (GE Healthcare).

N2a Cell culture and transfections. Neuro-2a cells (CCL-131, ATCC) were plated into 6-well plates at a density of 100,000 cells/well and allowed to attach overnight. Media was refreshed 30 mins prior to transfection. For transfection, 1μg plasmid (CAG-GFP control or one of four distinct shRab27a plasmids) was incubated at room temperature in serum-free DMEM with 3μL Polyjet (Signagen) for 15 mins. After 24 hrs, the cells were lysed, concentration determined by BCA protein assay (Sigma Aldrich) and prepared for Western Blot.

Fibroblast culture. Mouse tail snips were used for isolation of primary fibroblasts. Tails were cut into small pieces using scissors and placed in a conical tube with a solution of complete DMEM and collagenase. Pieces were placed in a shaking incubator at 37 °C for 90 mins, followed by manual grinding of tissue pieces. After tissue digestion, the solution was put through a cell strainer, centrifuged at 1,000 × g for 5 mins and cells were plated on standard tissue culture plates in pre-warmed complete DMEM.

Genotyping PCR. DNA samples were incubated in 75μL 50mM NaOH buffer at 50 °C until tissue is transparent. After incubation, 75μL of 100 mM Tris-HCl was added to samples. Samples were stored at −20 °C. The following primers were used: Tomato (AG GGA GCT GCA GTG GAG TA, CG AAA ATC TGT GGG AAG TC and GCC ATT AAA GCA GCG TAT CC, CTG TTC CTG TAC GGC ATG G), CRE (GGC GTC TGG CAG TAA AAA CTA TC, GTG AAA CAG CAT TGC TGT CAC TT and CTA GGC CAC AGA ATT GAA AGA TCT, GTA GGT GGA AAT TCT AGC ATC ATC C).

Microglia culture and EV treatments. 24 hr prior to plating microglia, 6 well plates were coated with 10μg/mL poly-L-lysine. Microglia isolated from CD1 mice were plated in complete media (2ng/mL TGF-b2, 100ng/mL IL-34, 1.5μg/mL cholesterol, 100 units/mL penicillin-streptomycin, Glutamax, and microglia media [Sciencell, 1901]) and allowed to adhere for 10 min at RT. For cytokine assays, 1.66 × 10⁶ cells per well on 6 well plates and treated 24 hrs later. EVs were isolated from astrocytes plated at a density of 1.66 × 10⁶ cells per well of a 6 well plate in 3 mLs per well. 3 mLs of astrocyte conditioned media was subjected to EV isolation, resuspended in 50μL media (27.6 × 10⁶ EVs in 50μL), and added to microglia cultured in 3 mLs of media per well in 6 well plates. 24 hrs later, media was collected and depleted of all EVs and cytokine assays performed.

Cytokine assay. Cytokine concentrations were quantified with the cytokine multiplex assay from Bio-Rad as recently described. Wells of a 96 well filter plate were loaded with 50μL of prepared standard solution or 50μL of cell-free supernatant and incubated with the Bio-Plex Pro mouse 23-plex assay from Bio-Rad at 800 rpm for 20–30 mins. The primers for 5′ targeting are 5′-TCATCAAGGAAACCTGGAC-3′ and for 3′ targeting are 5′-AACGACTGTCCTGCTCTCA-3′ and 5′-TAGTTGCCAGCCTCGTTTTGTT-3′.

Statistics. Statistics were performed with Prism software (version 7; GraphPad). Significance was calculated using unpaired t tests or one-way ANOVA with Tukey's multiple comparisons test. All data are presented as mean ± SEM. Heat maps and hierarchical clustering analysis was performed using the University of California at Santa Cruz Banana Slug Analytics Platform.

References
1. Morton, M. C. & Feliciano, D. M. Neurovesicles in Brain Development. Cell. Mol. Neurobiol. 36 (2016).
2. Feliciano, D. M., Zhang, S., Nasrallah, C. M., Ligo, S. N. & Bordey, A. Embryonic cerebrospinal fluid nanovesicles carry evolutionarily conserved molecules and promote neural stem cell amplification. PLoS One 9 (2014).
3. Tietje, A., Maron, K. N., Wei, Y. & Feliciano, D. M. Cerebrospinal fluid extracellular vesicles undergo age dependent declines and contain known and novel non-coding RNAs. PLoS One 9 (2014).
4. Morton, M. C., Neckles, V. N., Soluzicki, C. M., Holmberg, J. C. & Feliciano, D. M. Neonatal Subventricular Zone Neural Stem Cells Release Extracellular Vesicles that Act as a Microglial Morphogen. Cell Rep., https://doi.org/10.1016/j.celrep.2018.03.037 (2018).
5. Morton, M. C., Neckles, V. N. & Feliciano, D. M. P.D. Isolation of Extracellular Vesicles from Subventricular Zone Neural Stem Cells. Methods Mol. Biol. STEM CELL (2018).
6. Feliciano, D. M. & Bordey, A. Newborn cortical neurons: Only for neonates? Trends Neurosci. 36 (2013).
7. Sanai, N. et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 478, 382–386 (2011).
8. Shigemoto-Mogami, Y., Hoshikawa, K., Goldman, J. E., Sekino, Y. & Sato, K. Microglia Enhance Neurogenesis and Oligodendrogenesis in the Early Postnatal Subventricular Zone. J. Neurosci. 34, 2231–2243 (2014).
9. Cunningham, C. L., Martinez-Cerdeño, V. & Noctor, S. C. Microglia regulate the number of neural precursor cells in the developing cerebral cortex. J. Neurosci. 33, 4216–33 (2013).
10. Barger, N. et al. Microglia: An Intrinsic Component of the Proliferative Zones in the Fetal Rhesus Monkey (Macaca mulatta) Cerebral Cortex. Cereb. Cortex, https://doi.org/10.1093/cercor/bhy145 (2018).
31. Yoshimura, A.
32. Dickens, A. M.
30. Yoshimura, A.
29. Mittelbrunn, M.
27. Panáková, D., Sprong, H., Marois, E., Thiele, C. & Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling.
28. Gross, J. C., Chaudhary, V., Bartscherer, K. & Boutros, M. Active Wnt proteins are secreted on exosomes.
34. Haderk, F.
25. Kowal, J.
24. Escola, J. M.
23. Théry, C.
22. Wubbolts, R.
19. Lagace, D. C.
11. Monier, A.
10. Szüts, Y. & Schwab, M. E. Astrocytes sense and respond to synaptic activity in vivo.
9. Vinals, F.
8. Hayashi, S. & McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: A tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244, 305–318 (2002).
7. Lagace, D. C. et al. Dynamic Contribution of Nestin-Expressing Stem Cells to Adult Neurogenesis. J. Neurosci. 27, 12623–12629 (2007).
6. Boisvert, M. M., Erikson, G. A., Shokhirev, M. N. & Allen, N. J. The Aging Astrocyte Transcriptorne from Multiple Regions of the Mouse Brain. Cell Rep. 22, 269–285 (2018).
5. Friedman, B. A. et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models. Cell Rep. 22, 832–847 (2018).
4. Wubbolts, R. et al. Proteomic and biochemical analyses of human B cell-derived exosomes: Potential implications for their function and multivesicular body formation. J. Biol. Chem. 278, 10963–10972 (2003).
3. Théry, C. et al. Molecular characterization of dendritic cell-derived exosomes: Selective accumulation of the heat shock protein hsc73. J. Cell Biol. 147, 599–610 (1999).
2. Escola, J. M. et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 273, 20121–20127 (1998).
1. Kowal, J. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl. Acad. Sci. 113, E968–E977 (2016).
Raposo, G. & Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. Journal of Cell Biology 200, 373–383 (2013).
Panáková, D., Spong, H., Marois, E., Thiele, C. & Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 435, 58–65 (2005).
Gross, J. C., Chaudhary, V., Bartscherer, K. & Boutros, M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 14, 1036–1045 (2012).
Mittelbrunn, M. et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2 (2011).
Yoshimura, A. et al. Generation of a novel transgenic rat model for tracing extracellular vesicles in body fluids. Sci. Rep. 6 (2016).
Yoshimura, A. et al. The Sox2 promoter-driven CD63-GFP transgenic rat model allows tracking of neural stem cell-derived extracellular vesicles. Dis. Model. Mech. 11, dmm028779 (2018).
Dickens, A. M. et al. Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. Sci. Signal. 10 (2017).
Rickles, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4 (2018).
Haderk, F. et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci. Immunol. 2, eaah5599 (2017).

Acknowledgements

David M. Feliciano is supported by grants from the Whitehall Foundation and National Institutes of Health R15NS096562.

Author Contributions

Conceptualization, D.M.F., T.N.; Methodology, D.M.F., V.N.N., T.N., D.L., J.C.H., A.M.S. and M.C.M.; Validation, D.M.F., M.C.M., C.M.S., J.C.H., A.M.S., D.L. and V.N.N.; Formal Analysis, V.N.N.; Investigation, M.C.M., V.N.N., D.M.F., J.C.H. and C.M.S.; Writing – Original Draft, D.M.F. and V.N.N.; Writing – Review & Editing, D.M.F. and V.N.N.; Visualization, V.N.N. and D.M.F.; Supervision, D.M.F.; Project Administration, D.M.F., V.N.N. and J.C.H.; Funding Acquisition, D.M.F.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-39679-0. Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019